ReviewJournal of inflammation research2026
Revisiting the Subtle Relationship Between Metabolic Syndrome and Osteoarthritis.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteoarthritis (OA) is a common disabling joint disorder traditionally attributed to mechanical wear. Emerging evidence shows that metabolic syndrome (MetS) and its components-obesity, hypertension, hyperglycemia, and dyslipidemia-are closely associated with OA onset and progression, suggesting that OA also has a metabolic-inflammatory nature. Main Text: This review highlights mechanisms linking each MetS component to OA. Obesity contributes not only by increasing joint load but also through adipokines such as leptin, resistin, and visfatin, which activate inflammatory pathways and promote cartilage degradation and synovitis. Hypertension may worsen OA via joint ischemia, oxidative stress, and renin-angiotensin system activation. Hyperglycemia damages cartilage and ligaments by promoting advanced glycation end product accumulation and oxidative stress. Dyslipidemia influences OA through cholesterol deposition and inflammatory responses. Metabolic inflammation and immunometabolic reprogramming further drive OA progression. Conclusion: MetS and OA are interconnected through mechanical stress, adipokine activity, inflammatory signaling, and metabolic dysregulation. Future studies should clarify how MetS affects pain, subchondral bone remodeling, and other OA phenotypes, aiding the development of individualized, metabolism-targeted strategies for early intervention and comprehensive OA management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.